Patient preferences can be indicators of treatment success and quality. |
The golimumab GO-SAVE trial employed active surveillance to comparatively examine patient satisfaction among biologic products in rheumatoid arthritis (RA). |
Most patients with RA who transitioned to golimumab from adalimumab or etanercept were satisfied with their overall golimumab experience. |